organization · Reporting owner
Fullerton Management Pte Ltd
Disclosed activity across 10 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Coherus Oncology, Inc.CHRS · Entity 6276 | 10% owner | December 30, 2019 | January 08, 2020 |
| Flywire CorpFLYW · Entity 1568 | 10% owner | May 28, 2021 | June 01, 2021 |
| Pear Therapeutics, Inc.PEAR · Entity 114512 | 10% owner | December 03, 2021 | December 10, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Coherus Oncology, Inc.
Report date December 30, 2019 · Filed January 08, 2020
Jointly reported with V-Sciences Investments Pte Ltd, Temasek Life Sciences Private Ltd, Temasek Holdings (Private) Ltd
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,381,116 |
Reported balance
Holding disclosure · report date 2019-12-30 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 7,381,116 F1: V-Sciences Investments Pte Ltd ("V-Sciences") directly owns 7,381,116 shares of Issuer's common stock. V-Sciences is a wholly-owned subsidiary of Temasek Life Sciences Private Limited ("Temasek Life Sciences"), which is a wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which is a wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek"). Each of Temasek Life Sciences, FMPL and Temasek, through the ownership described herein, may be deemed to beneficially own the shares held by V-Sciences. |
Filing footnotes · ownership attribution and instrument terms
F1: V-Sciences Investments Pte Ltd ("V-Sciences") directly owns 7,381,116 shares of Issuer's common stock. V-Sciences is a wholly-owned subsidiary of Temasek Life Sciences Private Limited ("Temasek Life Sciences"), which is a wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which is a wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek"). Each of Temasek Life Sciences, FMPL and Temasek, through the ownership described herein, may be deemed to beneficially own the shares held by V-Sciences.
Flywire Corp
Report date May 28, 2021 · Filed June 01, 2021
Jointly reported with Ossa Investments Pte. Ltd., Hotham Investments Pte. Ltd., Temasek Holdings (Private) Ltd
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A common stockSEC Table I · non-derivative | Direct | 0 |
Last balance in matching sequence
After 2021-05-28 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2021-05-28 · Conversion · Acquired 9,514,293 · Balance 10,635,573 F1: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F2: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments. Row 3 · 2021-05-28 · Other · Disposed 10,635,573 · Balance 0 F1: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F2: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments. |
| Class B common stockSEC Table I · non-derivative | Direct | 0 |
Last balance in matching sequence
After 2021-05-28 transaction · row 5
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 2 · 2021-05-28 · Conversion · Acquired 1,873,320 · Balance 1,873,320 F1: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F2: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments. Row 5 · 2021-05-28 · Other · Disposed 1,873,320 · Balance 0 F1: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F2: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments. |
| Voting common stockSEC Table I · non-derivative | Direct | 10,635,573 |
Reported balance
After 2021-05-28 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2021-05-28 · Other · Acquired 10,635,573 · Balance 10,635,573 F1: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F2: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments. |
| Non-voting common stockSEC Table I · non-derivative | Direct | 1,873,320 |
Reported balance
After 2021-05-28 transaction · row 6
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 6 · 2021-05-28 · Other · Acquired 1,873,320 · Balance 1,873,320 F1: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F2: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments. |
| Series A preferred stockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-05-28 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-05-28 · Conversion · Disposed 97,173 · Balance 0 F1: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F2: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments. |
| Series B preferred stockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-05-28 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-05-28 · Conversion · Disposed 2,100,129 · Balance 0 F1: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F2: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments. |
| Series C preferred stockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-05-28 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2021-05-28 · Conversion · Disposed 547,008 · Balance 0 F1: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F2: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments. |
| Series D preferred stockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-05-28 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2021-05-28 · Conversion · Disposed 6,625,002 · Balance 0 F1: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F2: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments. |
| Series E-2 preferred stockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-05-28 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2021-05-28 · Conversion · Disposed 1,873,320 · Balance 0 F1: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F2: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments. |
| Series F preferred stockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-05-28 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2021-05-28 · Conversion · Disposed 144,981 · Balance 0 F1: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F2: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments. |
Filing footnotes · ownership attribution and instrument terms
F1: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7.
F2: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments.
Pear Therapeutics, Inc.
Report date December 03, 2021 · Filed December 10, 2021
Jointly reported with Temasek Holdings (Private) Ltd, TLS Beta Pte. Ltd., Temasek Life Sciences Private Ltd, Elbrus Investments Pte. Ltd.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | IndirectSee footnotes | 26,803,573 |
Reported balance
Holding disclosure · report date 2021-12-03 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 26,803,573 F1: The securities reported herein consist of 24,903,573 shares of Class A Common Stock of Pear Therapeutics, Inc. (the "Company") directly held by TLS Beta Pte. Ltd and 1,900,000 shares of Class A Common Stock of the Company directly held by Elbrus Investments Pte. Ltd. F2: Each of TLS Beta Pte. Ltd. and Elbrus Investments Pte. Ltd. is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited ("TLS"). TLS is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. TLS, FMPL and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by each of TLS Beta Pte. Ltd. and Elbrus Investments Pte. Ltd. Each Reporting Owner disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities reported herein consist of 24,903,573 shares of Class A Common Stock of Pear Therapeutics, Inc. (the "Company") directly held by TLS Beta Pte. Ltd and 1,900,000 shares of Class A Common Stock of the Company directly held by Elbrus Investments Pte. Ltd.
F2: Each of TLS Beta Pte. Ltd. and Elbrus Investments Pte. Ltd. is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited ("TLS"). TLS is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. TLS, FMPL and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by each of TLS Beta Pte. Ltd. and Elbrus Investments Pte. Ltd. Each Reporting Owner disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
Past disclosures · reporting ended (7)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AMYRIS, INC.
Report date May 07, 2018 · Filed May 09, 2018
Jointly reported with Munday Investments Pte. Ltd., Canhill Investments Pte. Ltd., Temasek Holdings (Private) Ltd
Section 16 reporting ended · disclosed 2018-05-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,207,423 |
Reported balance
After 2018-05-07 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2018-05-07 · Sale · Disposed 95,162 · Balance 3,207,423 F1: On June 5, 2017, the Issuer effected a fifteen-to-one reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F2: Maxwell (Mauritius) Pte Ltd directly owns these shares of Common Stock. Maxwell (Mauritius) Pte Ltd is wholly-owned by Cairnhill Investments (Mauritius) Pte Ltd, which in turn is wholly-owned by Fullerton Management Pte Ltd, which in turn is wholly-owned by Temasek Holdings (Private) Limited. Therefore, each of Temasek Holdings (Private) Limited, Fullerton Management Pte Ltd and Cairnhill Investments (Mauritius) Pte Ltd may be deemed to beneficially own the shares of Common Stock directly owned by Maxwell (Mauritius) Pte Ltd. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 5, 2017, the Issuer effected a fifteen-to-one reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
F2: Maxwell (Mauritius) Pte Ltd directly owns these shares of Common Stock. Maxwell (Mauritius) Pte Ltd is wholly-owned by Cairnhill Investments (Mauritius) Pte Ltd, which in turn is wholly-owned by Fullerton Management Pte Ltd, which in turn is wholly-owned by Temasek Holdings (Private) Limited. Therefore, each of Temasek Holdings (Private) Limited, Fullerton Management Pte Ltd and Cairnhill Investments (Mauritius) Pte Ltd may be deemed to beneficially own the shares of Common Stock directly owned by Maxwell (Mauritius) Pte Ltd.
Akili, Inc.
Report date July 02, 2024 · Filed July 05, 2024
Jointly reported with Temasek Holdings (Private) Ltd, TLS Beta Pte. Ltd., Temasek Life Sciences Private Ltd
Section 16 reporting ended · disclosed 2024-07-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001SEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2024-07-02 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-07-02 · Other · Disposed 10,336,425 · Balance 0 F1: Reflects disposition of shares of common stock (each, a "Share") of the Issuer at a price per Share of $0.4340 (the "Offer Price") pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 29, 2024, by and among the Issuer, Virtual Therapeutics Corporation, a Delaware corporation ("Parent") and Alpha Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of common stock of the Issuer and thereafter merged with and into the Issuer, effective as of July 2, 2024 (the "Effective Time"), with the Issuer surviving the merger. As of the Effective Time, each Share held by the Reporting Persons was converted into the Offer Price. F2: The securities reported herein were directly owned by TLS Beta Pte. Ltd. ("TLS Beta"), which is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited ("Temasek Life Sciences"). Temasek Life Sciences is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Temasek Life Sciences, FMPL and Temasek Holdings may therefore be deemed to have had or shared beneficial ownership of the securities directly owned by TLS Beta. |
| Earnout SharesSEC Table II · derivative / convertible security · Expires 2027-08-19 | IndirectSee Footnote | 0 |
Reported balance
After 2024-07-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-07-02 · Other · Disposed 1,172,697 · Balance 0 F3: Represents shares of the Issuer's common stock deposited into an escrow account for the benefit of TLS Beta (the "Earnout Shares") pursuant to the Agreement and Plan of Merger, dated as of January 26, 2022, by and among Social Capital Suvretta Holdings Corp. I, Karibu Merger Sub, Inc., and Akili Interactive Labs, Inc. The Earnout Shares were cancelled for no consideration pursuant to the terms of the Merger Agreement. F2: The securities reported herein were directly owned by TLS Beta Pte. Ltd. ("TLS Beta"), which is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited ("Temasek Life Sciences"). Temasek Life Sciences is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Temasek Life Sciences, FMPL and Temasek Holdings may therefore be deemed to have had or shared beneficial ownership of the securities directly owned by TLS Beta. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects disposition of shares of common stock (each, a "Share") of the Issuer at a price per Share of $0.4340 (the "Offer Price") pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 29, 2024, by and among the Issuer, Virtual Therapeutics Corporation, a Delaware corporation ("Parent") and Alpha Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of common stock of the Issuer and thereafter merged with and into the Issuer, effective as of July 2, 2024 (the "Effective Time"), with the Issuer surviving the merger. As of the Effective Time, each Share held by the Reporting Persons was converted into the Offer Price.
F2: The securities reported herein were directly owned by TLS Beta Pte. Ltd. ("TLS Beta"), which is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited ("Temasek Life Sciences"). Temasek Life Sciences is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Temasek Life Sciences, FMPL and Temasek Holdings may therefore be deemed to have had or shared beneficial ownership of the securities directly owned by TLS Beta.
F3: Represents shares of the Issuer's common stock deposited into an escrow account for the benefit of TLS Beta (the "Earnout Shares") pursuant to the Agreement and Plan of Merger, dated as of January 26, 2022, by and among Social Capital Suvretta Holdings Corp. I, Karibu Merger Sub, Inc., and Akili Interactive Labs, Inc. The Earnout Shares were cancelled for no consideration pursuant to the terms of the Merger Agreement.
Blend Labs, Inc.
Report date July 20, 2021 · Filed July 22, 2021
Jointly reported with Ossa Investments Pte. Ltd., Hotham Investments Pte. Ltd., Temasek Holdings (Private) Ltd
Section 16 reporting ended · disclosed 2021-07-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A common stockSEC Table I · non-derivative | Direct | 11,875,773 |
Reported balance
After 2021-07-20 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2021-07-20 · Conversion · Acquired 11,875,773 · Balance 11,875,773 F1: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock, each share of Class A common stock as then named was reclassified into one share of Class B common stock and each share of Class B common stock as then named was reclassified into one share of Class A common stock. This Form 4 assumes all shares had been renamed as if such reclassification had already occurred. F2: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock on July 20, 2021, each share of preferred stock automatically converted into one share of Class B common stock and thereafter into one share of Class A common stock without payment or further consideration and has no expiration date. F3: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments. |
| Series E convertible preferred stockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-07-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-07-20 · Conversion · Disposed 10,949,867 · Balance 0 F2: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock on July 20, 2021, each share of preferred stock automatically converted into one share of Class B common stock and thereafter into one share of Class A common stock without payment or further consideration and has no expiration date. F1: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock, each share of Class A common stock as then named was reclassified into one share of Class B common stock and each share of Class B common stock as then named was reclassified into one share of Class A common stock. This Form 4 assumes all shares had been renamed as if such reclassification had already occurred. F3: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments. |
| Series F convertible preferred stockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-07-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-07-20 · Conversion · Disposed 925,906 · Balance 0 F2: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock on July 20, 2021, each share of preferred stock automatically converted into one share of Class B common stock and thereafter into one share of Class A common stock without payment or further consideration and has no expiration date. F1: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock, each share of Class A common stock as then named was reclassified into one share of Class B common stock and each share of Class B common stock as then named was reclassified into one share of Class A common stock. This Form 4 assumes all shares had been renamed as if such reclassification had already occurred. F3: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments. |
| Class B common stockSEC Table II · derivative / convertible security | Direct | 11,875,773 |
Reported balance
After 2021-07-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-07-20 · Conversion · Acquired 11,875,773 · Balance 11,875,773 F1: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock, each share of Class A common stock as then named was reclassified into one share of Class B common stock and each share of Class B common stock as then named was reclassified into one share of Class A common stock. This Form 4 assumes all shares had been renamed as if such reclassification had already occurred. F2: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock on July 20, 2021, each share of preferred stock automatically converted into one share of Class B common stock and thereafter into one share of Class A common stock without payment or further consideration and has no expiration date. F3: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments. |
| Class B common stockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-07-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-07-20 · Conversion · Disposed 11,875,773 · Balance 0 F1: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock, each share of Class A common stock as then named was reclassified into one share of Class B common stock and each share of Class B common stock as then named was reclassified into one share of Class A common stock. This Form 4 assumes all shares had been renamed as if such reclassification had already occurred. F2: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock on July 20, 2021, each share of preferred stock automatically converted into one share of Class B common stock and thereafter into one share of Class A common stock without payment or further consideration and has no expiration date. F3: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments. |
Filing footnotes · ownership attribution and instrument terms
F1: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock, each share of Class A common stock as then named was reclassified into one share of Class B common stock and each share of Class B common stock as then named was reclassified into one share of Class A common stock. This Form 4 assumes all shares had been renamed as if such reclassification had already occurred.
F2: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock on July 20, 2021, each share of preferred stock automatically converted into one share of Class B common stock and thereafter into one share of Class A common stock without payment or further consideration and has no expiration date.
F3: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments.
Guardant Health, Inc.
Report date October 09, 2018 · Filed October 11, 2018
Jointly reported with TLS Beta Pte. Ltd., Temasek Life Sciences Private Ltd, Temasek Holdings (Private) Ltd
Section 16 reporting ended · disclosed 2018-10-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCKSEC Table I · non-derivative | IndirectBy TLS Beta Pte. Ltd. | 1,016,995 |
Reported balance
After 2018-10-09 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2018-10-09 · Conversion · Acquired 1,016,995 · Balance 1,016,995 F1: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date. F2: The shares are directly held by TLS Beta Pte. Ltd., which is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd, or FMPL, which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. Temasek Life Sciences Private Limited, FMPL and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta Pte. Ltd. |
| COMMON STOCKSEC Table I · non-derivative | IndirectBy TLS Beta Pte. Ltd. | 596,012 |
Reported balance
After 2018-10-09 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2018-10-09 · Conversion · Acquired 596,012 · Balance 596,012 F1: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date. F2: The shares are directly held by TLS Beta Pte. Ltd., which is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd, or FMPL, which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. Temasek Life Sciences Private Limited, FMPL and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta Pte. Ltd. |
| SERIES D PREFERRED STOCKSEC Table II · derivative / convertible security | IndirectBy TLS Beta Pte. Ltd. | 0 |
Reported balance
After 2018-10-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-10-09 · Conversion · Disposed 1,016,995 · Balance 0 F1: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date. F2: The shares are directly held by TLS Beta Pte. Ltd., which is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd, or FMPL, which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. Temasek Life Sciences Private Limited, FMPL and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta Pte. Ltd. |
| SERIES E PREFERRED STOCKSEC Table II · derivative / convertible security | IndirectBy TLS Beta Pte. Ltd. | 0 |
Reported balance
After 2018-10-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-10-09 · Conversion · Disposed 596,012 · Balance 0 F1: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date. F2: The shares are directly held by TLS Beta Pte. Ltd., which is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd, or FMPL, which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. Temasek Life Sciences Private Limited, FMPL and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta Pte. Ltd. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date.
F2: The shares are directly held by TLS Beta Pte. Ltd., which is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd, or FMPL, which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. Temasek Life Sciences Private Limited, FMPL and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta Pte. Ltd.
PORTOLA PHARMACEUTICALS INC
Report date June 01, 2017 · Filed June 05, 2017
Jointly reported with Munday Investments Pte. Ltd., Canhill Investments Pte. Ltd., Temasek Holdings (Private) Ltd
Section 16 reporting ended · disclosed 2017-06-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 4,133,568 |
Reported balance
After 2017-06-01 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2017-06-01 · Sale · Disposed 1,700,000 · Balance 4,133,568 F1: Maxwell (Mauritius) Pte Ltd ("Maxwell") owns 4,133,568 shares of the Issuer's common stock ("Shares") and V-Sciences Investments Pte Ltd ("V-Sciences") owns 750,000 Shares. Maxwell is wholly owned by Cairnhill Investments (Mauritius) Pte Ltd, which is wholly owned by Fullerton Management Pte Ltd ("FMPL"). V-Sciences is wholly owned by Temasek Life Sciences Private Limited, which is wholly owned by FMPL. FMPL is wholly owned by Temasek Holdings (Private) Limited. Accordingly, each of FMPL and Temasek Holdings (Private) Limited, through the ownership described herein, may be deemed to beneficially own the 4,883,568 Shares owned by Maxwell and V-Sciences, collectively. |
Filing footnotes · ownership attribution and instrument terms
F1: Maxwell (Mauritius) Pte Ltd ("Maxwell") owns 4,133,568 shares of the Issuer's common stock ("Shares") and V-Sciences Investments Pte Ltd ("V-Sciences") owns 750,000 Shares. Maxwell is wholly owned by Cairnhill Investments (Mauritius) Pte Ltd, which is wholly owned by Fullerton Management Pte Ltd ("FMPL"). V-Sciences is wholly owned by Temasek Life Sciences Private Limited, which is wholly owned by FMPL. FMPL is wholly owned by Temasek Holdings (Private) Limited. Accordingly, each of FMPL and Temasek Holdings (Private) Limited, through the ownership described herein, may be deemed to beneficially own the 4,883,568 Shares owned by Maxwell and V-Sciences, collectively.
Q32 Bio Inc.
Report date April 02, 2018 · Filed April 04, 2018
Jointly reported with Temasek Holdings (Private) Ltd, Temasek Life Sciences Private Ltd, TLS Beta Pte. Ltd., V-Sciences Investments Pte Ltd
Section 16 reporting ended · disclosed 2018-04-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,605,681 |
Reported balance
After 2018-04-02 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2018-04-02 · Conversion · Acquired 1,605,681 · Balance 1,605,681 F1: The Series A Preferred Stock of Homology Medicines, Inc. (the "Issuer") held of record by TLS Beta Pte. Ltd. ("TLS Beta") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A Preferred Stock, subject to adjustment and had no expiration date. F3: Consists of 1,605,681 shares of Common Stock held of record by TLS Beta. F6: TLS Beta is a direct wholly-owned subsidiary of TLS. TLS is a direct wholly-owned subsidiary of FMPL, which in turn is a direct wholly-owned subsidiary of Temasek. TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,595,293 |
Reported balance
After 2018-04-02 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2018-04-02 · Conversion · Acquired 989,612 · Balance 2,595,293 F2: The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date. F4: Consists of 989,612 shares of Common Stock held of record by TLS Beta. F6: TLS Beta is a direct wholly-owned subsidiary of TLS. TLS is a direct wholly-owned subsidiary of FMPL, which in turn is a direct wholly-owned subsidiary of Temasek. TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 3,220,293 |
Reported balance
After 2018-04-02 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2018-04-02 · Purchase · Acquired 625,000 · Balance 3,220,293 F5: Consists of 625,000 shares of Common Stock held of record by V-Sciences Investments Pte Ltd ("V-Sciences") which were purchased in the Issuer's initial public offering at a price of $16.00 per share. V-Sciences Investments Pte Ltd is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited ("TLS") is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek"). TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by V-Sciences. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnotes | 0 |
Reported balance
After 2018-04-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-04-02 · Conversion · Disposed 1,605,681 · Balance 0 F1: The Series A Preferred Stock of Homology Medicines, Inc. (the "Issuer") held of record by TLS Beta Pte. Ltd. ("TLS Beta") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A Preferred Stock, subject to adjustment and had no expiration date. F6: TLS Beta is a direct wholly-owned subsidiary of TLS. TLS is a direct wholly-owned subsidiary of FMPL, which in turn is a direct wholly-owned subsidiary of Temasek. TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnotes | 0 |
Reported balance
After 2018-04-02 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-04-02 · Conversion · Disposed 989,612 · Balance 0 F2: The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date. F6: TLS Beta is a direct wholly-owned subsidiary of TLS. TLS is a direct wholly-owned subsidiary of FMPL, which in turn is a direct wholly-owned subsidiary of Temasek. TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta. |
Filing footnotes · ownership attribution and instrument terms
F1: The Series A Preferred Stock of Homology Medicines, Inc. (the "Issuer") held of record by TLS Beta Pte. Ltd. ("TLS Beta") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A Preferred Stock, subject to adjustment and had no expiration date.
F2: The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date.
F3: Consists of 1,605,681 shares of Common Stock held of record by TLS Beta.
F4: Consists of 989,612 shares of Common Stock held of record by TLS Beta.
F5: Consists of 625,000 shares of Common Stock held of record by V-Sciences Investments Pte Ltd ("V-Sciences") which were purchased in the Issuer's initial public offering at a price of $16.00 per share. V-Sciences Investments Pte Ltd is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited ("TLS") is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek"). TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by V-Sciences.
F6: TLS Beta is a direct wholly-owned subsidiary of TLS. TLS is a direct wholly-owned subsidiary of FMPL, which in turn is a direct wholly-owned subsidiary of Temasek. TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta.
Vir Biotechnology, Inc.
Report date October 16, 2019 · Filed October 18, 2019
Jointly reported with Temasek Holdings (Private) Ltd, Temasek Life Sciences Private Ltd, TLS Beta Pte. Ltd., V-Sciences Investments Pte Ltd
Section 16 reporting ended · disclosed 2019-10-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 3,333,333 |
Reported balance
After 2019-10-16 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2019-10-16 · Conversion · Acquired 3,333,333 · Balance 3,333,333 F1: The Series A-1 Preferred Stock of Vir Biotechnology, Inc. (the "Issuer") held of record by TLS Beta Pte. Ltd. ("TLS Beta") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A-1 Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A-1 Preferred Stock, subject to adjustment and had no expiration date. F3: Consists of 3,333,333 shares of Common Stock held of record by TLS Beta. F6: TLS Beta is a direct wholly-owned subsidiary of TLS. TLS is a direct wholly-owned subsidiary of FMPL, which in turn is a direct wholly-owned subsidiary of Temasek. TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 4,999,999 |
Reported balance
After 2019-10-16 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2019-10-16 · Conversion · Acquired 1,666,666 · Balance 4,999,999 F2: The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date. F4: Consists of 1,666,666 shares of Common Stock held of record by TLS Beta. F6: TLS Beta is a direct wholly-owned subsidiary of TLS. TLS is a direct wholly-owned subsidiary of FMPL, which in turn is a direct wholly-owned subsidiary of Temasek. TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 5,499,999 |
Reported balance
After 2019-10-16 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2019-10-16 · Purchase · Acquired 500,000 · Balance 5,499,999 F5: Consists of 500,000 shares of Common Stock held of record by V-Sciences Investments Pte Ltd ("V-Sciences") which were purchased in the Issuer's initial public offering at a price of $20.00 per share. V-Sciences Investments Pte Ltd is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited ("TLS") is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek"). TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by V-Sciences. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. |
| Series A-1 Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnotes | 0 |
Reported balance
After 2019-10-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-10-16 · Conversion · Disposed 3,333,333 · Balance 0 F1: The Series A-1 Preferred Stock of Vir Biotechnology, Inc. (the "Issuer") held of record by TLS Beta Pte. Ltd. ("TLS Beta") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A-1 Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A-1 Preferred Stock, subject to adjustment and had no expiration date. F6: TLS Beta is a direct wholly-owned subsidiary of TLS. TLS is a direct wholly-owned subsidiary of FMPL, which in turn is a direct wholly-owned subsidiary of Temasek. TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnotes | 0 |
Reported balance
After 2019-10-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-10-16 · Conversion · Disposed 1,666,666 · Balance 0 F2: The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date. F6: TLS Beta is a direct wholly-owned subsidiary of TLS. TLS is a direct wholly-owned subsidiary of FMPL, which in turn is a direct wholly-owned subsidiary of Temasek. TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. |
Filing footnotes · ownership attribution and instrument terms
F1: The Series A-1 Preferred Stock of Vir Biotechnology, Inc. (the "Issuer") held of record by TLS Beta Pte. Ltd. ("TLS Beta") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A-1 Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A-1 Preferred Stock, subject to adjustment and had no expiration date.
F2: The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date.
F3: Consists of 3,333,333 shares of Common Stock held of record by TLS Beta.
F4: Consists of 1,666,666 shares of Common Stock held of record by TLS Beta.
F5: Consists of 500,000 shares of Common Stock held of record by V-Sciences Investments Pte Ltd ("V-Sciences") which were purchased in the Issuer's initial public offering at a price of $20.00 per share. V-Sciences Investments Pte Ltd is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited ("TLS") is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek"). TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by V-Sciences. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
F6: TLS Beta is a direct wholly-owned subsidiary of TLS. TLS is a direct wholly-owned subsidiary of FMPL, which in turn is a direct wholly-owned subsidiary of Temasek. TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 02, 2024 Filed Jul 5, 2024 15:54 UTC | Akili, Inc. AKLI · Entity 89130 | OtherEarnout Shares · Derivative | 1,172,697 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-081811 · ownership.xml · derivative · entry 2 Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner TLS Beta Pte. Ltd. · CIK 0001673754 · 10% owner Temasek Life Sciences Private Ltd · CIK 0001379349 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,172,697 shares Expires 2027-08-19 F3 · derivative.exercise_price: Represents shares of the Issuer's common stock deposited into an escrow account for the benefit of TLS Beta (the "Earnout Shares") pursuant to the Agreement and Plan of Merger, dated as of January 26, 2022, by and among Social Capital Suvretta Holdings Corp. I, Karibu Merger Sub, Inc., and Akili Interactive Labs, Inc. The Earnout Shares were cancelled for no consideration pursuant to the terms of the Merger Agreement. F3 · price: Represents shares of the Issuer's common stock deposited into an escrow account for the benefit of TLS Beta (the "Earnout Shares") pursuant to the Agreement and Plan of Merger, dated as of January 26, 2022, by and among Social Capital Suvretta Holdings Corp. I, Karibu Merger Sub, Inc., and Akili Interactive Labs, Inc. The Earnout Shares were cancelled for no consideration pursuant to the terms of the Merger Agreement. F3 · derivative.exercise_date: Represents shares of the Issuer's common stock deposited into an escrow account for the benefit of TLS Beta (the "Earnout Shares") pursuant to the Agreement and Plan of Merger, dated as of January 26, 2022, by and among Social Capital Suvretta Holdings Corp. I, Karibu Merger Sub, Inc., and Akili Interactive Labs, Inc. The Earnout Shares were cancelled for no consideration pursuant to the terms of the Merger Agreement. F2 · ownership.direct: The securities reported herein were directly owned by TLS Beta Pte. Ltd. ("TLS Beta"), which is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited ("Temasek Life Sciences"). Temasek Life Sciences is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Temasek Life Sciences, FMPL and Temasek Holdings may therefore be deemed to have had or shared beneficial ownership of the securities directly owned by TLS Beta. F2 · ownership.nature: The securities reported herein were directly owned by TLS Beta Pte. Ltd. ("TLS Beta"), which is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited ("Temasek Life Sciences"). Temasek Life Sciences is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Temasek Life Sciences, FMPL and Temasek Holdings may therefore be deemed to have had or shared beneficial ownership of the securities directly owned by TLS Beta. Read SEC document |
| July 02, 2024 Filed Jul 5, 2024 15:54 UTC | Akili, Inc. AKLI · Entity 89130 | OtherCommon Stock, par value $0.0001 | 10,336,425 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-081811 · ownership.xml · nonDerivative · entry 1 Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner TLS Beta Pte. Ltd. · CIK 0001673754 · 10% owner Temasek Life Sciences Private Ltd · CIK 0001379349 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · price: Reflects disposition of shares of common stock (each, a "Share") of the Issuer at a price per Share of $0.4340 (the "Offer Price") pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 29, 2024, by and among the Issuer, Virtual Therapeutics Corporation, a Delaware corporation ("Parent") and Alpha Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of common stock of the Issuer and thereafter merged with and into the Issuer, effective as of July 2, 2024 (the "Effective Time"), with the Issuer surviving the merger. As of the Effective Time, each Share held by the Reporting Persons was converted into the Offer Price. F2 · ownership.direct: The securities reported herein were directly owned by TLS Beta Pte. Ltd. ("TLS Beta"), which is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited ("Temasek Life Sciences"). Temasek Life Sciences is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Temasek Life Sciences, FMPL and Temasek Holdings may therefore be deemed to have had or shared beneficial ownership of the securities directly owned by TLS Beta. F2 · ownership.nature: The securities reported herein were directly owned by TLS Beta Pte. Ltd. ("TLS Beta"), which is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited ("Temasek Life Sciences"). Temasek Life Sciences is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Temasek Life Sciences, FMPL and Temasek Holdings may therefore be deemed to have had or shared beneficial ownership of the securities directly owned by TLS Beta. Read SEC document |
| July 20, 2021 Filed Jul 22, 2021 10:06 UTC | Blend Labs, Inc. BLND · Entity 5752 | ConversionClass B common stock · Derivative | 11,875,773 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-029426 · doc4.xml · derivative · entry 5 Ossa Investments Pte. Ltd. · CIK 0001810133 · 10% owner Hotham Investments Pte. Ltd. · CIK 0001810114 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A common stock · 11,875,773 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock, each share of Class A common stock as then named was reclassified into one share of Class B common stock and each share of Class B common stock as then named was reclassified into one share of Class A common stock. This Form 4 assumes all shares had been renamed as if such reclassification had already occurred. F2 · derivative.exercise_price: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock on July 20, 2021, each share of preferred stock automatically converted into one share of Class B common stock and thereafter into one share of Class A common stock without payment or further consideration and has no expiration date. F1 · kind: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock, each share of Class A common stock as then named was reclassified into one share of Class B common stock and each share of Class B common stock as then named was reclassified into one share of Class A common stock. This Form 4 assumes all shares had been renamed as if such reclassification had already occurred. F2 · kind: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock on July 20, 2021, each share of preferred stock automatically converted into one share of Class B common stock and thereafter into one share of Class A common stock without payment or further consideration and has no expiration date. F2 · price: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock on July 20, 2021, each share of preferred stock automatically converted into one share of Class B common stock and thereafter into one share of Class A common stock without payment or further consideration and has no expiration date. F2 · derivative.exercise_date: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock on July 20, 2021, each share of preferred stock automatically converted into one share of Class B common stock and thereafter into one share of Class A common stock without payment or further consideration and has no expiration date. F2 · derivative.expiration_date: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock on July 20, 2021, each share of preferred stock automatically converted into one share of Class B common stock and thereafter into one share of Class A common stock without payment or further consideration and has no expiration date. F3 · ownership.direct: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments. Read SEC document |
| July 20, 2021 Filed Jul 22, 2021 10:06 UTC | Blend Labs, Inc. BLND · Entity 5752 | ConversionClass B common stock · Derivative | 11,875,773 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-029426 · doc4.xml · derivative · entry 4 Ossa Investments Pte. Ltd. · CIK 0001810133 · 10% owner Hotham Investments Pte. Ltd. · CIK 0001810114 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,875,773 Underlying: Class A common stock · 11,875,773 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock, each share of Class A common stock as then named was reclassified into one share of Class B common stock and each share of Class B common stock as then named was reclassified into one share of Class A common stock. This Form 4 assumes all shares had been renamed as if such reclassification had already occurred. F2 · derivative.exercise_price: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock on July 20, 2021, each share of preferred stock automatically converted into one share of Class B common stock and thereafter into one share of Class A common stock without payment or further consideration and has no expiration date. F1 · kind: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock, each share of Class A common stock as then named was reclassified into one share of Class B common stock and each share of Class B common stock as then named was reclassified into one share of Class A common stock. This Form 4 assumes all shares had been renamed as if such reclassification had already occurred. F2 · kind: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock on July 20, 2021, each share of preferred stock automatically converted into one share of Class B common stock and thereafter into one share of Class A common stock without payment or further consideration and has no expiration date. F2 · price: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock on July 20, 2021, each share of preferred stock automatically converted into one share of Class B common stock and thereafter into one share of Class A common stock without payment or further consideration and has no expiration date. F2 · derivative.exercise_date: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock on July 20, 2021, each share of preferred stock automatically converted into one share of Class B common stock and thereafter into one share of Class A common stock without payment or further consideration and has no expiration date. F2 · derivative.expiration_date: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock on July 20, 2021, each share of preferred stock automatically converted into one share of Class B common stock and thereafter into one share of Class A common stock without payment or further consideration and has no expiration date. F3 · ownership.direct: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments. Read SEC document |
| July 20, 2021 Filed Jul 22, 2021 10:06 UTC | Blend Labs, Inc. BLND · Entity 5752 | ConversionSeries F convertible preferred stock · Derivative | 925,906 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-029426 · doc4.xml · derivative · entry 3 Ossa Investments Pte. Ltd. · CIK 0001810133 · 10% owner Hotham Investments Pte. Ltd. · CIK 0001810114 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class B common stock · 925,906 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock on July 20, 2021, each share of preferred stock automatically converted into one share of Class B common stock and thereafter into one share of Class A common stock without payment or further consideration and has no expiration date. F1 · kind: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock, each share of Class A common stock as then named was reclassified into one share of Class B common stock and each share of Class B common stock as then named was reclassified into one share of Class A common stock. This Form 4 assumes all shares had been renamed as if such reclassification had already occurred. F2 · kind: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock on July 20, 2021, each share of preferred stock automatically converted into one share of Class B common stock and thereafter into one share of Class A common stock without payment or further consideration and has no expiration date. F2 · price: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock on July 20, 2021, each share of preferred stock automatically converted into one share of Class B common stock and thereafter into one share of Class A common stock without payment or further consideration and has no expiration date. F2 · derivative.exercise_date: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock on July 20, 2021, each share of preferred stock automatically converted into one share of Class B common stock and thereafter into one share of Class A common stock without payment or further consideration and has no expiration date. F2 · derivative.expiration_date: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock on July 20, 2021, each share of preferred stock automatically converted into one share of Class B common stock and thereafter into one share of Class A common stock without payment or further consideration and has no expiration date. F1 · derivative.underlying: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock, each share of Class A common stock as then named was reclassified into one share of Class B common stock and each share of Class B common stock as then named was reclassified into one share of Class A common stock. This Form 4 assumes all shares had been renamed as if such reclassification had already occurred. F3 · ownership.direct: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments. Read SEC document |
| July 20, 2021 Filed Jul 22, 2021 10:06 UTC | Blend Labs, Inc. BLND · Entity 5752 | ConversionSeries E convertible preferred stock · Derivative | 10,949,867 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-029426 · doc4.xml · derivative · entry 2 Ossa Investments Pte. Ltd. · CIK 0001810133 · 10% owner Hotham Investments Pte. Ltd. · CIK 0001810114 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class B common stock · 10,949,867 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock on July 20, 2021, each share of preferred stock automatically converted into one share of Class B common stock and thereafter into one share of Class A common stock without payment or further consideration and has no expiration date. F1 · kind: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock, each share of Class A common stock as then named was reclassified into one share of Class B common stock and each share of Class B common stock as then named was reclassified into one share of Class A common stock. This Form 4 assumes all shares had been renamed as if such reclassification had already occurred. F2 · kind: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock on July 20, 2021, each share of preferred stock automatically converted into one share of Class B common stock and thereafter into one share of Class A common stock without payment or further consideration and has no expiration date. F2 · price: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock on July 20, 2021, each share of preferred stock automatically converted into one share of Class B common stock and thereafter into one share of Class A common stock without payment or further consideration and has no expiration date. F2 · derivative.exercise_date: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock on July 20, 2021, each share of preferred stock automatically converted into one share of Class B common stock and thereafter into one share of Class A common stock without payment or further consideration and has no expiration date. F2 · derivative.expiration_date: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock on July 20, 2021, each share of preferred stock automatically converted into one share of Class B common stock and thereafter into one share of Class A common stock without payment or further consideration and has no expiration date. F1 · derivative.underlying: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock, each share of Class A common stock as then named was reclassified into one share of Class B common stock and each share of Class B common stock as then named was reclassified into one share of Class A common stock. This Form 4 assumes all shares had been renamed as if such reclassification had already occurred. F3 · ownership.direct: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments. Read SEC document |
| July 20, 2021 Filed Jul 22, 2021 10:06 UTC | Blend Labs, Inc. BLND · Entity 5752 | ConversionClass A common stock | 11,875,773 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-029426 · doc4.xml · nonDerivative · entry 1 Ossa Investments Pte. Ltd. · CIK 0001810133 · 10% owner Hotham Investments Pte. Ltd. · CIK 0001810114 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,875,773 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock, each share of Class A common stock as then named was reclassified into one share of Class B common stock and each share of Class B common stock as then named was reclassified into one share of Class A common stock. This Form 4 assumes all shares had been renamed as if such reclassification had already occurred. F1 · kind: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock, each share of Class A common stock as then named was reclassified into one share of Class B common stock and each share of Class B common stock as then named was reclassified into one share of Class A common stock. This Form 4 assumes all shares had been renamed as if such reclassification had already occurred. F2 · kind: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock on July 20, 2021, each share of preferred stock automatically converted into one share of Class B common stock and thereafter into one share of Class A common stock without payment or further consideration and has no expiration date. F2 · price: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock on July 20, 2021, each share of preferred stock automatically converted into one share of Class B common stock and thereafter into one share of Class A common stock without payment or further consideration and has no expiration date. F3 · ownership.direct: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments. Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 10:06 UTC | Flywire Corp FLYW · Entity 1568 | ConversionSeries F preferred stock · Derivative | 144,981 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-021235 · doc4.xml · derivative · entry 12 Ossa Investments Pte. Ltd. · CIK 0001810133 · 10% owner Hotham Investments Pte. Ltd. · CIK 0001810114 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A common stock · 144,981 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F1 · price: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F1 · derivative.exercise_date: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F1 · derivative.expiration_date: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F1 · derivative.underlying_shares: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F2 · ownership.direct: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments. Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 10:06 UTC | Flywire Corp FLYW · Entity 1568 | ConversionSeries E-2 preferred stock · Derivative | 1,873,320 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-021235 · doc4.xml · derivative · entry 11 Ossa Investments Pte. Ltd. · CIK 0001810133 · 10% owner Hotham Investments Pte. Ltd. · CIK 0001810114 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class B common stock · 1,873,320 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F1 · price: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F1 · derivative.exercise_date: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F1 · derivative.expiration_date: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F1 · derivative.underlying_shares: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F2 · ownership.direct: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments. Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 10:06 UTC | Flywire Corp FLYW · Entity 1568 | ConversionSeries D preferred stock · Derivative | 6,625,002 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-021235 · doc4.xml · derivative · entry 10 Ossa Investments Pte. Ltd. · CIK 0001810133 · 10% owner Hotham Investments Pte. Ltd. · CIK 0001810114 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A common stock · 6,625,002 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F1 · price: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F1 · derivative.exercise_date: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F1 · derivative.expiration_date: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F1 · derivative.underlying_shares: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F2 · ownership.direct: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments. Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 10:06 UTC | Flywire Corp FLYW · Entity 1568 | ConversionSeries C preferred stock · Derivative | 547,008 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-021235 · doc4.xml · derivative · entry 9 Ossa Investments Pte. Ltd. · CIK 0001810133 · 10% owner Hotham Investments Pte. Ltd. · CIK 0001810114 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A common stock · 547,008 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F1 · price: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F1 · derivative.exercise_date: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F1 · derivative.expiration_date: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F1 · derivative.underlying_shares: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F2 · ownership.direct: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments. Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 10:06 UTC | Flywire Corp FLYW · Entity 1568 | ConversionSeries B preferred stock · Derivative | 2,100,129 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-021235 · doc4.xml · derivative · entry 8 Ossa Investments Pte. Ltd. · CIK 0001810133 · 10% owner Hotham Investments Pte. Ltd. · CIK 0001810114 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A common stock · 2,100,129 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F1 · price: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F1 · derivative.exercise_date: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F1 · derivative.expiration_date: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F1 · derivative.underlying_shares: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F2 · ownership.direct: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments. Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 10:06 UTC | Flywire Corp FLYW · Entity 1568 | ConversionSeries A preferred stock · Derivative | 97,173 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-021235 · doc4.xml · derivative · entry 7 Ossa Investments Pte. Ltd. · CIK 0001810133 · 10% owner Hotham Investments Pte. Ltd. · CIK 0001810114 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A common stock · 97,173 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F1 · price: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F1 · derivative.exercise_date: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F1 · derivative.expiration_date: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F1 · derivative.underlying_shares: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F2 · ownership.direct: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments. Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 10:06 UTC | Flywire Corp FLYW · Entity 1568 | OtherNon-voting common stock | 1,873,320 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-021235 · doc4.xml · nonDerivative · entry 6 Ossa Investments Pte. Ltd. · CIK 0001810133 · 10% owner Hotham Investments Pte. Ltd. · CIK 0001810114 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,873,320 F1 · kind: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F1 · price: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F2 · ownership.direct: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments. Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 10:06 UTC | Flywire Corp FLYW · Entity 1568 | OtherClass B common stock | 1,873,320 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-021235 · doc4.xml · nonDerivative · entry 5 Ossa Investments Pte. Ltd. · CIK 0001810133 · 10% owner Hotham Investments Pte. Ltd. · CIK 0001810114 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F1 · price: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F2 · ownership.direct: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments. Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 10:06 UTC | Flywire Corp FLYW · Entity 1568 | OtherVoting common stock | 10,635,573 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-021235 · doc4.xml · nonDerivative · entry 4 Ossa Investments Pte. Ltd. · CIK 0001810133 · 10% owner Hotham Investments Pte. Ltd. · CIK 0001810114 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,635,573 F1 · kind: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F1 · price: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F2 · ownership.direct: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments. Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 10:06 UTC | Flywire Corp FLYW · Entity 1568 | OtherClass A common stock | 10,635,573 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-021235 · doc4.xml · nonDerivative · entry 3 Ossa Investments Pte. Ltd. · CIK 0001810133 · 10% owner Hotham Investments Pte. Ltd. · CIK 0001810114 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F1 · price: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F2 · ownership.direct: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments. Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 10:06 UTC | Flywire Corp FLYW · Entity 1568 | ConversionClass B common stock | 1,873,320 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-021235 · doc4.xml · nonDerivative · entry 2 Ossa Investments Pte. Ltd. · CIK 0001810133 · 10% owner Hotham Investments Pte. Ltd. · CIK 0001810114 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,873,320 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F2 · ownership.direct: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments. Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 10:06 UTC | Flywire Corp FLYW · Entity 1568 | ConversionClass A common stock | 9,514,293 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-021235 · doc4.xml · nonDerivative · entry 1 Ossa Investments Pte. Ltd. · CIK 0001810133 · 10% owner Hotham Investments Pte. Ltd. · CIK 0001810114 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,635,573 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F2 · ownership.direct: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments. Read SEC document |
| October 16, 2019 Filed Oct 18, 2019 20:16 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | ConversionSeries B Preferred Stock · Derivative | 1,666,666 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-025766 · doc4.xml · derivative · entry 5 Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Life Sciences Private Ltd · CIK 0001379349 · 10% owner TLS Beta Pte. Ltd. · CIK 0001673754 · 10% owner V-Sciences Investments Pte Ltd · CIK 0001379350 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 1,666,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date. F2 · shares: The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date. F2 · price: The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date. F2 · derivative.exercise_date: The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date. F2 · derivative.expiration_date: The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date. F2 · ownership.nature: The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date. F6 · ownership.nature: TLS Beta is a direct wholly-owned subsidiary of TLS. TLS is a direct wholly-owned subsidiary of FMPL, which in turn is a direct wholly-owned subsidiary of Temasek. TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| October 16, 2019 Filed Oct 18, 2019 20:16 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | ConversionSeries A-1 Preferred Stock · Derivative | 3,333,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-025766 · doc4.xml · derivative · entry 4 Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Life Sciences Private Ltd · CIK 0001379349 · 10% owner TLS Beta Pte. Ltd. · CIK 0001673754 · 10% owner V-Sciences Investments Pte Ltd · CIK 0001379350 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 3,333,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A-1 Preferred Stock of Vir Biotechnology, Inc. (the "Issuer") held of record by TLS Beta Pte. Ltd. ("TLS Beta") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A-1 Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A-1 Preferred Stock, subject to adjustment and had no expiration date. F1 · shares: The Series A-1 Preferred Stock of Vir Biotechnology, Inc. (the "Issuer") held of record by TLS Beta Pte. Ltd. ("TLS Beta") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A-1 Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A-1 Preferred Stock, subject to adjustment and had no expiration date. F1 · price: The Series A-1 Preferred Stock of Vir Biotechnology, Inc. (the "Issuer") held of record by TLS Beta Pte. Ltd. ("TLS Beta") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A-1 Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A-1 Preferred Stock, subject to adjustment and had no expiration date. F1 · derivative.exercise_date: The Series A-1 Preferred Stock of Vir Biotechnology, Inc. (the "Issuer") held of record by TLS Beta Pte. Ltd. ("TLS Beta") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A-1 Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A-1 Preferred Stock, subject to adjustment and had no expiration date. F1 · derivative.expiration_date: The Series A-1 Preferred Stock of Vir Biotechnology, Inc. (the "Issuer") held of record by TLS Beta Pte. Ltd. ("TLS Beta") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A-1 Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A-1 Preferred Stock, subject to adjustment and had no expiration date. F1 · ownership.nature: The Series A-1 Preferred Stock of Vir Biotechnology, Inc. (the "Issuer") held of record by TLS Beta Pte. Ltd. ("TLS Beta") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A-1 Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A-1 Preferred Stock, subject to adjustment and had no expiration date. F6 · ownership.nature: TLS Beta is a direct wholly-owned subsidiary of TLS. TLS is a direct wholly-owned subsidiary of FMPL, which in turn is a direct wholly-owned subsidiary of Temasek. TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| October 16, 2019 Filed Oct 18, 2019 20:16 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | PurchaseCommon Stock | 500,000 | $20.00 | $10,000,000.00 |
DisclosureSEC source: 0000899243-19-025766 · doc4.xml · nonDerivative · entry 3 Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Life Sciences Private Ltd · CIK 0001379349 · 10% owner TLS Beta Pte. Ltd. · CIK 0001673754 · 10% owner V-Sciences Investments Pte Ltd · CIK 0001379350 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 5,499,999 F5 · ownership.nature: Consists of 500,000 shares of Common Stock held of record by V-Sciences Investments Pte Ltd ("V-Sciences") which were purchased in the Issuer's initial public offering at a price of $20.00 per share. V-Sciences Investments Pte Ltd is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited ("TLS") is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek"). TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by V-Sciences. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| October 16, 2019 Filed Oct 18, 2019 20:16 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | ConversionCommon Stock | 1,666,666 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-025766 · doc4.xml · nonDerivative · entry 2 Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Life Sciences Private Ltd · CIK 0001379349 · 10% owner TLS Beta Pte. Ltd. · CIK 0001673754 · 10% owner V-Sciences Investments Pte Ltd · CIK 0001379350 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 4,999,999 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date. F4 · ownership.nature: Consists of 1,666,666 shares of Common Stock held of record by TLS Beta. F6 · ownership.nature: TLS Beta is a direct wholly-owned subsidiary of TLS. TLS is a direct wholly-owned subsidiary of FMPL, which in turn is a direct wholly-owned subsidiary of Temasek. TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| October 16, 2019 Filed Oct 18, 2019 20:16 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | ConversionCommon Stock | 3,333,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-025766 · doc4.xml · nonDerivative · entry 1 Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Life Sciences Private Ltd · CIK 0001379349 · 10% owner TLS Beta Pte. Ltd. · CIK 0001673754 · 10% owner V-Sciences Investments Pte Ltd · CIK 0001379350 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,333,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A-1 Preferred Stock of Vir Biotechnology, Inc. (the "Issuer") held of record by TLS Beta Pte. Ltd. ("TLS Beta") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A-1 Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A-1 Preferred Stock, subject to adjustment and had no expiration date. F3 · ownership.nature: Consists of 3,333,333 shares of Common Stock held of record by TLS Beta. F6 · ownership.nature: TLS Beta is a direct wholly-owned subsidiary of TLS. TLS is a direct wholly-owned subsidiary of FMPL, which in turn is a direct wholly-owned subsidiary of Temasek. TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| October 09, 2018 Filed Oct 11, 2018 20:29 UTC | Guardant Health, Inc. GH · Entity 3238 | ConversionSERIES E PREFERRED STOCK · Derivative | 596,012 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-18-012483 · wf-form4_153928972789967.xml · derivative · entry 4 TLS Beta Pte. Ltd. · CIK 0001673754 · 10% owner Temasek Life Sciences Private Ltd · CIK 0001379349 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By TLS Beta Pte. Ltd. Disclosed balance after: 0 Underlying: COMMON STOCK · 596,012 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date. F1 · price: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date. F1 · derivative.exercise_date: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date. F1 · derivative.expiration_date: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date. F2 · ownership.direct: The shares are directly held by TLS Beta Pte. Ltd., which is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd, or FMPL, which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. Temasek Life Sciences Private Limited, FMPL and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta Pte. Ltd. F2 · ownership.nature: The shares are directly held by TLS Beta Pte. Ltd., which is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd, or FMPL, which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. Temasek Life Sciences Private Limited, FMPL and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta Pte. Ltd. Read SEC document |
| October 09, 2018 Filed Oct 11, 2018 20:29 UTC | Guardant Health, Inc. GH · Entity 3238 | ConversionSERIES D PREFERRED STOCK · Derivative | 1,016,995 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-18-012483 · wf-form4_153928972789967.xml · derivative · entry 3 TLS Beta Pte. Ltd. · CIK 0001673754 · 10% owner Temasek Life Sciences Private Ltd · CIK 0001379349 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By TLS Beta Pte. Ltd. Disclosed balance after: 0 Underlying: COMMON STOCK · 1,016,995 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date. F1 · price: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date. F1 · derivative.exercise_date: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date. F1 · derivative.expiration_date: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date. F2 · ownership.direct: The shares are directly held by TLS Beta Pte. Ltd., which is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd, or FMPL, which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. Temasek Life Sciences Private Limited, FMPL and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta Pte. Ltd. F2 · ownership.nature: The shares are directly held by TLS Beta Pte. Ltd., which is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd, or FMPL, which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. Temasek Life Sciences Private Limited, FMPL and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta Pte. Ltd. Read SEC document |
| October 09, 2018 Filed Oct 11, 2018 20:29 UTC | Guardant Health, Inc. GH · Entity 3238 | ConversionCOMMON STOCK | 596,012 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-18-012483 · wf-form4_153928972789967.xml · nonDerivative · entry 2 TLS Beta Pte. Ltd. · CIK 0001673754 · 10% owner Temasek Life Sciences Private Ltd · CIK 0001379349 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By TLS Beta Pte. Ltd. Disclosed balance after: 596,012 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date. F2 · ownership.direct: The shares are directly held by TLS Beta Pte. Ltd., which is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd, or FMPL, which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. Temasek Life Sciences Private Limited, FMPL and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta Pte. Ltd. F2 · ownership.nature: The shares are directly held by TLS Beta Pte. Ltd., which is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd, or FMPL, which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. Temasek Life Sciences Private Limited, FMPL and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta Pte. Ltd. Read SEC document |
| October 09, 2018 Filed Oct 11, 2018 20:29 UTC | Guardant Health, Inc. GH · Entity 3238 | ConversionCOMMON STOCK | 1,016,995 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-18-012483 · wf-form4_153928972789967.xml · nonDerivative · entry 1 TLS Beta Pte. Ltd. · CIK 0001673754 · 10% owner Temasek Life Sciences Private Ltd · CIK 0001379349 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By TLS Beta Pte. Ltd. Disclosed balance after: 1,016,995 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date. F2 · ownership.direct: The shares are directly held by TLS Beta Pte. Ltd., which is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd, or FMPL, which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. Temasek Life Sciences Private Limited, FMPL and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta Pte. Ltd. F2 · ownership.nature: The shares are directly held by TLS Beta Pte. Ltd., which is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd, or FMPL, which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. Temasek Life Sciences Private Limited, FMPL and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta Pte. Ltd. Read SEC document |
| May 07, 2018 Filed May 9, 2018 13:29 UTC | AMYRIS, INC. AMRS · Entity 91367 | SaleCommon Stock | 95,162 | $6.54 | $622,635.45 |
DisclosureSEC source: 0000899243-18-012036 · doc4.xml · nonDerivative · entry 1 Maxwell (Mauritius) Pte Ltd · CIK 0001512375 · 10% owner Cairnhill Investments (Mauritius) Pte Ltd · CIK 0001434871 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,207,423 F1 · balance_after: On June 5, 2017, the Issuer effected a fifteen-to-one reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F2 · ownership.direct: Maxwell (Mauritius) Pte Ltd directly owns these shares of Common Stock. Maxwell (Mauritius) Pte Ltd is wholly-owned by Cairnhill Investments (Mauritius) Pte Ltd, which in turn is wholly-owned by Fullerton Management Pte Ltd, which in turn is wholly-owned by Temasek Holdings (Private) Limited. Therefore, each of Temasek Holdings (Private) Limited, Fullerton Management Pte Ltd and Cairnhill Investments (Mauritius) Pte Ltd may be deemed to beneficially own the shares of Common Stock directly owned by Maxwell (Mauritius) Pte Ltd. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 17:33 UTC | Q32 Bio Inc. FIXX · Entity 5594 | ConversionSeries B Preferred Stock · Derivative | 989,612 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-009413 · doc4.xml · derivative · entry 5 Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Life Sciences Private Ltd · CIK 0001379349 · 10% owner TLS Beta Pte. Ltd. · CIK 0001673754 · 10% owner V-Sciences Investments Pte Ltd · CIK 0001379350 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 989,612 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date. F2 · shares: The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date. F2 · price: The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date. F2 · derivative.exercise_date: The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date. F2 · derivative.expiration_date: The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date. F2 · ownership.nature: The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date. F6 · ownership.nature: TLS Beta is a direct wholly-owned subsidiary of TLS. TLS is a direct wholly-owned subsidiary of FMPL, which in turn is a direct wholly-owned subsidiary of Temasek. TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 17:33 UTC | Q32 Bio Inc. FIXX · Entity 5594 | ConversionSeries A Preferred Stock · Derivative | 1,605,681 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-009413 · doc4.xml · derivative · entry 4 Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Life Sciences Private Ltd · CIK 0001379349 · 10% owner TLS Beta Pte. Ltd. · CIK 0001673754 · 10% owner V-Sciences Investments Pte Ltd · CIK 0001379350 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 1,605,681 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A Preferred Stock of Homology Medicines, Inc. (the "Issuer") held of record by TLS Beta Pte. Ltd. ("TLS Beta") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A Preferred Stock, subject to adjustment and had no expiration date. F1 · shares: The Series A Preferred Stock of Homology Medicines, Inc. (the "Issuer") held of record by TLS Beta Pte. Ltd. ("TLS Beta") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A Preferred Stock, subject to adjustment and had no expiration date. F1 · price: The Series A Preferred Stock of Homology Medicines, Inc. (the "Issuer") held of record by TLS Beta Pte. Ltd. ("TLS Beta") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A Preferred Stock, subject to adjustment and had no expiration date. F1 · derivative.exercise_date: The Series A Preferred Stock of Homology Medicines, Inc. (the "Issuer") held of record by TLS Beta Pte. Ltd. ("TLS Beta") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A Preferred Stock, subject to adjustment and had no expiration date. F1 · derivative.expiration_date: The Series A Preferred Stock of Homology Medicines, Inc. (the "Issuer") held of record by TLS Beta Pte. Ltd. ("TLS Beta") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A Preferred Stock, subject to adjustment and had no expiration date. F1 · ownership.nature: The Series A Preferred Stock of Homology Medicines, Inc. (the "Issuer") held of record by TLS Beta Pte. Ltd. ("TLS Beta") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A Preferred Stock, subject to adjustment and had no expiration date. F6 · ownership.nature: TLS Beta is a direct wholly-owned subsidiary of TLS. TLS is a direct wholly-owned subsidiary of FMPL, which in turn is a direct wholly-owned subsidiary of Temasek. TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 17:33 UTC | Q32 Bio Inc. FIXX · Entity 5594 | PurchaseCommon Stock | 625,000 | $16.00 | $10,000,000.00 |
DisclosureSEC source: 0000899243-18-009413 · doc4.xml · nonDerivative · entry 3 Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Life Sciences Private Ltd · CIK 0001379349 · 10% owner TLS Beta Pte. Ltd. · CIK 0001673754 · 10% owner V-Sciences Investments Pte Ltd · CIK 0001379350 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,220,293 F5 · ownership.nature: Consists of 625,000 shares of Common Stock held of record by V-Sciences Investments Pte Ltd ("V-Sciences") which were purchased in the Issuer's initial public offering at a price of $16.00 per share. V-Sciences Investments Pte Ltd is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited ("TLS") is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek"). TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by V-Sciences. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 17:33 UTC | Q32 Bio Inc. FIXX · Entity 5594 | ConversionCommon Stock | 989,612 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-009413 · doc4.xml · nonDerivative · entry 2 Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Life Sciences Private Ltd · CIK 0001379349 · 10% owner TLS Beta Pte. Ltd. · CIK 0001673754 · 10% owner V-Sciences Investments Pte Ltd · CIK 0001379350 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,595,293 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date. F4 · ownership.nature: Consists of 989,612 shares of Common Stock held of record by TLS Beta. F6 · ownership.nature: TLS Beta is a direct wholly-owned subsidiary of TLS. TLS is a direct wholly-owned subsidiary of FMPL, which in turn is a direct wholly-owned subsidiary of Temasek. TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 17:33 UTC | Q32 Bio Inc. FIXX · Entity 5594 | ConversionCommon Stock | 1,605,681 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-009413 · doc4.xml · nonDerivative · entry 1 Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Life Sciences Private Ltd · CIK 0001379349 · 10% owner TLS Beta Pte. Ltd. · CIK 0001673754 · 10% owner V-Sciences Investments Pte Ltd · CIK 0001379350 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,605,681 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A Preferred Stock of Homology Medicines, Inc. (the "Issuer") held of record by TLS Beta Pte. Ltd. ("TLS Beta") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A Preferred Stock, subject to adjustment and had no expiration date. F3 · ownership.nature: Consists of 1,605,681 shares of Common Stock held of record by TLS Beta. F6 · ownership.nature: TLS Beta is a direct wholly-owned subsidiary of TLS. TLS is a direct wholly-owned subsidiary of FMPL, which in turn is a direct wholly-owned subsidiary of Temasek. TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 12:01 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | SaleCommon stock | 1,700,000 | $34.40 | $58,480,000.00 |
DisclosureSEC source: 0000899243-17-015234 · doc4.xml · nonDerivative · entry 1 Maxwell (Mauritius) Pte Ltd · CIK 0001512375 · 10% owner Cairnhill Investments (Mauritius) Pte Ltd · CIK 0001434871 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,133,568 F1 · ownership.direct: Maxwell (Mauritius) Pte Ltd ("Maxwell") owns 4,133,568 shares of the Issuer's common stock ("Shares") and V-Sciences Investments Pte Ltd ("V-Sciences") owns 750,000 Shares. Maxwell is wholly owned by Cairnhill Investments (Mauritius) Pte Ltd, which is wholly owned by Fullerton Management Pte Ltd ("FMPL"). V-Sciences is wholly owned by Temasek Life Sciences Private Limited, which is wholly owned by FMPL. FMPL is wholly owned by Temasek Holdings (Private) Limited. Accordingly, each of FMPL and Temasek Holdings (Private) Limited, through the ownership described herein, may be deemed to beneficially own the 4,883,568 Shares owned by Maxwell and V-Sciences, collectively. Read SEC document |
| May 05, 2017 Filed May 9, 2017 18:00 UTC | AMYRIS, INC. AMRS · Entity 91367 | Other6.50% Convertible Senior Notes due 2019 (the "Notes") · Derivative | Not disclosed | $0.00 Strike: $3.74 | $10,000,000.00 |
DisclosureSEC source: 0000899243-17-012448 · doc4.xml · derivative · entry 1 Maxwell (Mauritius) Pte Ltd · CIK 0001512375 · 10% owner Cairnhill Investments (Mauritius) Pte Ltd · CIK 0001434871 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · Not disclosed shares Expires not disclosed F1 · derivative.exercise_price: On May 5, 2017, Maxwell (Mauritius) Pte Ltd ("Maxwell"), the holder of the Notes, entered into a letter agreement with Amyris, Inc. ("Amyris") whereby Amyris agreed to pay in cash any portion of the Notes that remains outstanding on the maturity date, and Maxwell waived its right to convert the Notes into shares of Amyris common stock. Under the terms of the Notes, based on the initial conversion rate, the Notes were convertible into 2,670,370 shares of Amyris common stock. The termination of convertibility of the Notes could be deemed a "disposition" of a derivative security and/or the underlying common stock for purposes of Section 16 under the Securities Exchange Act of 1934, and the rules thereunder, and is reported herein solely for that reason. F1 · kind: On May 5, 2017, Maxwell (Mauritius) Pte Ltd ("Maxwell"), the holder of the Notes, entered into a letter agreement with Amyris, Inc. ("Amyris") whereby Amyris agreed to pay in cash any portion of the Notes that remains outstanding on the maturity date, and Maxwell waived its right to convert the Notes into shares of Amyris common stock. Under the terms of the Notes, based on the initial conversion rate, the Notes were convertible into 2,670,370 shares of Amyris common stock. The termination of convertibility of the Notes could be deemed a "disposition" of a derivative security and/or the underlying common stock for purposes of Section 16 under the Securities Exchange Act of 1934, and the rules thereunder, and is reported herein solely for that reason. F1 · reported_value: On May 5, 2017, Maxwell (Mauritius) Pte Ltd ("Maxwell"), the holder of the Notes, entered into a letter agreement with Amyris, Inc. ("Amyris") whereby Amyris agreed to pay in cash any portion of the Notes that remains outstanding on the maturity date, and Maxwell waived its right to convert the Notes into shares of Amyris common stock. Under the terms of the Notes, based on the initial conversion rate, the Notes were convertible into 2,670,370 shares of Amyris common stock. The termination of convertibility of the Notes could be deemed a "disposition" of a derivative security and/or the underlying common stock for purposes of Section 16 under the Securities Exchange Act of 1934, and the rules thereunder, and is reported herein solely for that reason. F1 · price: On May 5, 2017, Maxwell (Mauritius) Pte Ltd ("Maxwell"), the holder of the Notes, entered into a letter agreement with Amyris, Inc. ("Amyris") whereby Amyris agreed to pay in cash any portion of the Notes that remains outstanding on the maturity date, and Maxwell waived its right to convert the Notes into shares of Amyris common stock. Under the terms of the Notes, based on the initial conversion rate, the Notes were convertible into 2,670,370 shares of Amyris common stock. The termination of convertibility of the Notes could be deemed a "disposition" of a derivative security and/or the underlying common stock for purposes of Section 16 under the Securities Exchange Act of 1934, and the rules thereunder, and is reported herein solely for that reason. F1 · derivative.exercise_date: On May 5, 2017, Maxwell (Mauritius) Pte Ltd ("Maxwell"), the holder of the Notes, entered into a letter agreement with Amyris, Inc. ("Amyris") whereby Amyris agreed to pay in cash any portion of the Notes that remains outstanding on the maturity date, and Maxwell waived its right to convert the Notes into shares of Amyris common stock. Under the terms of the Notes, based on the initial conversion rate, the Notes were convertible into 2,670,370 shares of Amyris common stock. The termination of convertibility of the Notes could be deemed a "disposition" of a derivative security and/or the underlying common stock for purposes of Section 16 under the Securities Exchange Act of 1934, and the rules thereunder, and is reported herein solely for that reason. F1 · derivative.expiration_date: On May 5, 2017, Maxwell (Mauritius) Pte Ltd ("Maxwell"), the holder of the Notes, entered into a letter agreement with Amyris, Inc. ("Amyris") whereby Amyris agreed to pay in cash any portion of the Notes that remains outstanding on the maturity date, and Maxwell waived its right to convert the Notes into shares of Amyris common stock. Under the terms of the Notes, based on the initial conversion rate, the Notes were convertible into 2,670,370 shares of Amyris common stock. The termination of convertibility of the Notes could be deemed a "disposition" of a derivative security and/or the underlying common stock for purposes of Section 16 under the Securities Exchange Act of 1934, and the rules thereunder, and is reported herein solely for that reason. F2 · ownership.direct: Maxwell directly owns the Notes. Maxwell is wholly-owned by Cairnhill Investments (Mauritius) Pte Ltd., which in turn is wholly-owned by Fullerton Management Pte Ltd, which in turn is wholly-owned by Temasek Holdings (Private) Limited. Therefore, each of Temasek Holdings (Private) Limited, Fullerton Management Pte Ltd and Cairnhill Investments (Mauritius) Pte Ltd. may be deemed to beneficially own the shares of derivative securities directly owned by Maxwell. Read SEC document |
| April 20, 2017 Filed Apr 21, 2017 10:05 UTC | AMYRIS, INC. AMRS · Entity 91367 | SaleCommon Stock | 313,649 | $0.51 | $160,839.21 |
DisclosureSEC source: 0000899243-17-010671 · doc4.xml · nonDerivative · entry 2 Maxwell (Mauritius) Pte Ltd · CIK 0001512375 · 10% owner Cairnhill Investments (Mauritius) Pte Ltd · CIK 0001434871 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,538,771 F1 · ownership.direct: Maxwell (Mauritius) Pte Ltd directly owns 49,538,771 shares of Common Stock. Maxwell (Mauritius) Pte Ltd is wholly-owned by Cairnhill Investments (Mauritius) Pte Ltd, which in turn is wholly-owned by Fullerton Management Pte Ltd, which in turn is wholly-owned by Temasek Holdings (Private) Limited. Therefore, each of Temasek Holdings (Private) Limited, Fullerton Management Pte Ltd and Cairnhill Investments (Mauritius) Pte Ltd may be deemed to beneficially own the shares of Common Stock directly owned by Maxwell (Mauritius) Pte Ltd. Read SEC document |
| April 19, 2017 Filed Apr 21, 2017 10:05 UTC | AMYRIS, INC. AMRS · Entity 91367 | SaleCommon Stock | 338,864 | $0.59 | $198,438.76 |
DisclosureSEC source: 0000899243-17-010671 · doc4.xml · nonDerivative · entry 1 Maxwell (Mauritius) Pte Ltd · CIK 0001512375 · 10% owner Cairnhill Investments (Mauritius) Pte Ltd · CIK 0001434871 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,852,420 F1 · ownership.direct: Maxwell (Mauritius) Pte Ltd directly owns 49,538,771 shares of Common Stock. Maxwell (Mauritius) Pte Ltd is wholly-owned by Cairnhill Investments (Mauritius) Pte Ltd, which in turn is wholly-owned by Fullerton Management Pte Ltd, which in turn is wholly-owned by Temasek Holdings (Private) Limited. Therefore, each of Temasek Holdings (Private) Limited, Fullerton Management Pte Ltd and Cairnhill Investments (Mauritius) Pte Ltd may be deemed to beneficially own the shares of Common Stock directly owned by Maxwell (Mauritius) Pte Ltd. Read SEC document |
| April 18, 2017 Filed Apr 19, 2017 13:09 UTC | AMYRIS, INC. AMRS · Entity 91367 | SaleCommon Stock | 699,705 | $0.61 | $425,000.82 |
DisclosureSEC source: 0000899243-17-010505 · doc4.xml · nonDerivative · entry 2 Maxwell (Mauritius) Pte Ltd · CIK 0001512375 · 10% owner Cairnhill Investments (Mauritius) Pte Ltd · CIK 0001434871 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,191,284 F1 · ownership.direct: Maxwell (Mauritius) Pte Ltd directly owns 50,191,284 shares of Common Stock. Maxwell (Mauritius) Pte Ltd is wholly-owned by Cairnhill Investments (Mauritius) Pte Ltd, which in turn is wholly-owned by Fullerton Management Pte Ltd, which in turn is wholly-owned by Temasek Holdings (Private) Limited. Therefore, each of Temasek Holdings (Private) Limited, Fullerton Management Pte Ltd and Cairnhill Investments (Mauritius) Pte Ltd may be deemed to beneficially own the shares of Common Stock directly owned by Maxwell (Mauritius) Pte Ltd. Read SEC document |
| April 17, 2017 Filed Apr 19, 2017 13:09 UTC | AMYRIS, INC. AMRS · Entity 91367 | SaleCommon Stock | 937,225 | $0.68 | $640,218.40 |
DisclosureSEC source: 0000899243-17-010505 · doc4.xml · nonDerivative · entry 1 Maxwell (Mauritius) Pte Ltd · CIK 0001512375 · 10% owner Cairnhill Investments (Mauritius) Pte Ltd · CIK 0001434871 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,890,989 F1 · ownership.direct: Maxwell (Mauritius) Pte Ltd directly owns 50,191,284 shares of Common Stock. Maxwell (Mauritius) Pte Ltd is wholly-owned by Cairnhill Investments (Mauritius) Pte Ltd, which in turn is wholly-owned by Fullerton Management Pte Ltd, which in turn is wholly-owned by Temasek Holdings (Private) Limited. Therefore, each of Temasek Holdings (Private) Limited, Fullerton Management Pte Ltd and Cairnhill Investments (Mauritius) Pte Ltd may be deemed to beneficially own the shares of Common Stock directly owned by Maxwell (Mauritius) Pte Ltd. Read SEC document |
| March 30, 2017 Filed Apr 3, 2017 10:11 UTC | AMYRIS, INC. AMRS · Entity 91367 | SaleCommon Stock | 184,535 | $0.51 | $94,481.92 |
DisclosureSEC source: 0000899243-17-009072 · doc4.xml · nonDerivative · entry 1 Maxwell (Mauritius) Pte Ltd · CIK 0001512375 · 10% owner Cairnhill Investments (Mauritius) Pte Ltd · CIK 0001434871 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,828,214 F1 · ownership.direct: Maxwell (Mauritius) Pte Ltd directly owns 51,828,214 shares of Common Stock. Maxwell (Mauritius) Pte Ltd is wholly-owned by Cairnhill Investments (Mauritius) Pte Ltd, which in turn is wholly-owned by Fullerton Management Pte Ltd, which in turn is wholly-owned by Temasek Holdings (Private) Limited. Therefore, each of Temasek Holdings (Private) Limited, Fullerton Management Pte Ltd and Cairnhill Investments (Mauritius) Pte Ltd may be deemed to beneficially own the shares of Common Stock directly owned by Maxwell (Mauritius) Pte Ltd. Read SEC document |
| March 29, 2017 Filed Mar 30, 2017 12:21 UTC | AMYRIS, INC. AMRS · Entity 91367 | SaleCommon Stock | 300,470 | $0.52 | $155,643.46 |
DisclosureSEC source: 0000899243-17-008874 · doc4.xml · nonDerivative · entry 2 Maxwell (Mauritius) Pte Ltd · CIK 0001512375 · 10% owner Cairnhill Investments (Mauritius) Pte Ltd · CIK 0001434871 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,012,749 F1 · ownership.direct: Maxwell (Mauritius) Pte Ltd directly owns 52,012,749 shares of Common Stock. Maxwell (Mauritius) Pte Ltd is wholly-owned by Cairnhill Investments (Mauritius) Pte Ltd, which in turn is wholly-owned by Fullerton Management Pte Ltd, which in turn is wholly-owned by Temasek Holdings (Private) Limited. Therefore, each of Temasek Holdings (Private) Limited, Fullerton Management Pte Ltd and Cairnhill Investments (Mauritius) Pte Ltd may be deemed to beneficially own the shares of Common Stock directly owned by Maxwell (Mauritius) Pte Ltd. Read SEC document |
| March 28, 2017 Filed Mar 30, 2017 12:21 UTC | AMYRIS, INC. AMRS · Entity 91367 | SaleCommon Stock | 117,520 | $0.48 | $56,914.94 |
DisclosureSEC source: 0000899243-17-008874 · doc4.xml · nonDerivative · entry 1 Maxwell (Mauritius) Pte Ltd · CIK 0001512375 · 10% owner Cairnhill Investments (Mauritius) Pte Ltd · CIK 0001434871 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,313,219 F1 · ownership.direct: Maxwell (Mauritius) Pte Ltd directly owns 52,012,749 shares of Common Stock. Maxwell (Mauritius) Pte Ltd is wholly-owned by Cairnhill Investments (Mauritius) Pte Ltd, which in turn is wholly-owned by Fullerton Management Pte Ltd, which in turn is wholly-owned by Temasek Holdings (Private) Limited. Therefore, each of Temasek Holdings (Private) Limited, Fullerton Management Pte Ltd and Cairnhill Investments (Mauritius) Pte Ltd may be deemed to beneficially own the shares of Common Stock directly owned by Maxwell (Mauritius) Pte Ltd. Read SEC document |
| March 27, 2017 Filed Mar 28, 2017 11:00 UTC | AMYRIS, INC. AMRS · Entity 91367 | SaleCommon Stock | 86,613 | $0.48 | $41,920.69 |
DisclosureSEC source: 0000899243-17-008742 · doc4.xml · nonDerivative · entry 2 Maxwell (Mauritius) Pte Ltd · CIK 0001512375 · 10% owner Cairnhill Investments (Mauritius) Pte Ltd · CIK 0001434871 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,430,739 F1 · ownership.direct: Maxwell (Mauritius) Pte Ltd directly owns 52,430,739 shares of Common Stock. Maxwell (Mauritius) Pte Ltd is wholly-owned by Cairnhill Investments (Mauritius) Pte Ltd, which in turn is wholly-owned by Fullerton Management Pte Ltd, which in turn is wholly-owned by Temasek Holdings (Private) Limited. Therefore, each of Temasek Holdings (Private) Limited, Fullerton Management Pte Ltd and Cairnhill Investments (Mauritius) Pte Ltd may be deemed to beneficially own the shares of Common Stock directly owned by Maxwell (Mauritius) Pte Ltd. Read SEC document |
| March 24, 2017 Filed Mar 28, 2017 11:00 UTC | AMYRIS, INC. AMRS · Entity 91367 | SaleCommon Stock | 42,446 | $0.48 | $20,543.86 |
DisclosureSEC source: 0000899243-17-008742 · doc4.xml · nonDerivative · entry 1 Maxwell (Mauritius) Pte Ltd · CIK 0001512375 · 10% owner Cairnhill Investments (Mauritius) Pte Ltd · CIK 0001434871 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,517,352 F1 · ownership.direct: Maxwell (Mauritius) Pte Ltd directly owns 52,430,739 shares of Common Stock. Maxwell (Mauritius) Pte Ltd is wholly-owned by Cairnhill Investments (Mauritius) Pte Ltd, which in turn is wholly-owned by Fullerton Management Pte Ltd, which in turn is wholly-owned by Temasek Holdings (Private) Limited. Therefore, each of Temasek Holdings (Private) Limited, Fullerton Management Pte Ltd and Cairnhill Investments (Mauritius) Pte Ltd may be deemed to beneficially own the shares of Common Stock directly owned by Maxwell (Mauritius) Pte Ltd. Read SEC document |
| March 23, 2017 Filed Mar 24, 2017 10:44 UTC | AMYRIS, INC. AMRS · Entity 91367 | SaleCommon Stock | 43,482 | $0.49 | $21,110.51 |
DisclosureSEC source: 0000899243-17-008462 · doc4.xml · nonDerivative · entry 2 Maxwell (Mauritius) Pte Ltd · CIK 0001512375 · 10% owner Cairnhill Investments (Mauritius) Pte Ltd · CIK 0001434871 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,559,798 F1 · ownership.direct: Maxwell (Mauritius) Pte Ltd directly owns 52,559,798 shares of Common Stock. Maxwell (Mauritius) Pte Ltd is wholly-owned by Cairnhill Investments (Mauritius) Pte Ltd, which in turn is wholly-owned by Fullerton Management Pte Ltd, which in turn is wholly-owned by Temasek Holdings (Private) Limited. Therefore, each of Temasek Holdings (Private) Limited, Fullerton Management Pte Ltd and Cairnhill Investments (Mauritius) Pte Ltd may be deemed to beneficially own the shares of Common Stock directly owned by Maxwell (Mauritius) Pte Ltd. Read SEC document |
| March 22, 2017 Filed Mar 24, 2017 10:44 UTC | AMYRIS, INC. AMRS · Entity 91367 | SaleCommon Stock | 121,946 | $0.47 | $57,875.57 |
DisclosureSEC source: 0000899243-17-008462 · doc4.xml · nonDerivative · entry 1 Maxwell (Mauritius) Pte Ltd · CIK 0001512375 · 10% owner Cairnhill Investments (Mauritius) Pte Ltd · CIK 0001434871 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,603,280 F1 · ownership.direct: Maxwell (Mauritius) Pte Ltd directly owns 52,559,798 shares of Common Stock. Maxwell (Mauritius) Pte Ltd is wholly-owned by Cairnhill Investments (Mauritius) Pte Ltd, which in turn is wholly-owned by Fullerton Management Pte Ltd, which in turn is wholly-owned by Temasek Holdings (Private) Limited. Therefore, each of Temasek Holdings (Private) Limited, Fullerton Management Pte Ltd and Cairnhill Investments (Mauritius) Pte Ltd may be deemed to beneficially own the shares of Common Stock directly owned by Maxwell (Mauritius) Pte Ltd. Read SEC document |
| March 21, 2017 Filed Mar 22, 2017 10:06 UTC | AMYRIS, INC. AMRS · Entity 91367 | SaleCommon Stock | 134,691 | $0.48 | $64,678.62 |
DisclosureSEC source: 0000899243-17-008328 · doc4.xml · nonDerivative · entry 2 Maxwell (Mauritius) Pte Ltd · CIK 0001512375 · 10% owner Cairnhill Investments (Mauritius) Pte Ltd · CIK 0001434871 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,725,226 F1 · ownership.direct: Maxwell (Mauritius) Pte Ltd directly owns 52,725,226 shares of Common Stock. Maxwell (Mauritius) Pte Ltd is wholly-owned by Cairnhill Investments (Mauritius) Pte Ltd, which in turn is wholly-owned by Fullerton Management Pte Ltd, which in turn is wholly-owned by Temasek Holdings (Private) Limited. Therefore, each of Temasek Holdings (Private) Limited, Fullerton Management Pte Ltd and Cairnhill Investments (Mauritius) Pte Ltd may be deemed to beneficially own the shares of Common Stock directly owned by Maxwell (Mauritius) Pte Ltd. Read SEC document |
| March 20, 2017 Filed Mar 22, 2017 10:06 UTC | AMYRIS, INC. AMRS · Entity 91367 | SaleCommon Stock | 88,382 | $0.49 | $43,395.56 |
DisclosureSEC source: 0000899243-17-008328 · doc4.xml · nonDerivative · entry 1 Maxwell (Mauritius) Pte Ltd · CIK 0001512375 · 10% owner Cairnhill Investments (Mauritius) Pte Ltd · CIK 0001434871 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,859,917 F1 · ownership.direct: Maxwell (Mauritius) Pte Ltd directly owns 52,725,226 shares of Common Stock. Maxwell (Mauritius) Pte Ltd is wholly-owned by Cairnhill Investments (Mauritius) Pte Ltd, which in turn is wholly-owned by Fullerton Management Pte Ltd, which in turn is wholly-owned by Temasek Holdings (Private) Limited. Therefore, each of Temasek Holdings (Private) Limited, Fullerton Management Pte Ltd and Cairnhill Investments (Mauritius) Pte Ltd may be deemed to beneficially own the shares of Common Stock directly owned by Maxwell (Mauritius) Pte Ltd. Read SEC document |
| March 17, 2017 Filed Mar 20, 2017 12:37 UTC | AMYRIS, INC. AMRS · Entity 91367 | SaleCommon Stock | 153,108 | $0.49 | $75,543.49 |
DisclosureSEC source: 0000899243-17-008171 · doc4.xml · nonDerivative · entry 2 Maxwell (Mauritius) Pte Ltd · CIK 0001512375 · 10% owner Cairnhill Investments (Mauritius) Pte Ltd · CIK 0001434871 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,948,299 F1 · ownership.direct: Maxwell (Mauritius) Pte Ltd directly owns 52,948,299 shares of Common Stock. Maxwell (Mauritius) Pte Ltd is wholly-owned by Cairnhill Investments (Mauritius) Pte Ltd, which in turn is wholly-owned by Fullerton Management Pte Ltd, which in turn is wholly-owned by Temasek Holdings (Private) Limited. Therefore, each of Temasek Holdings (Private) Limited, Fullerton Management Pte Ltd and Cairnhill Investments (Mauritius) Pte Ltd may be deemed to beneficially own the shares of Common Stock directly owned by Maxwell (Mauritius) Pte Ltd. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.